Overview:Helsinn is a privately-owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland, USA and China. Founded in 1976, the company has become known worldwide for its unique business model focused on the licensing of innovative pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. The Group in-licenses early to late stage new chemical entities, completes their development from the performance of pre-clinical/clinical studies and Chemistry, Manufacturing and Control (CMC), development to the filing for and attainment of their market approval worldwide. Helsinn’s products are out-licensed to its network of local marketing and commercial partners worldwide, selected for their deep in-market knowledge and know-how, and assisted and supported with a full range of product and scientific management services, including commercial, regulatory, financial, legal and medical marketing advice. The active pharmaceutical ingredients and the finished dosage forms are manufactured ( www.helsinn.com/state-of-the-art-manufacturing ) at Helsinn’s cGMP facilities in Switzerland and Ireland, and supplied worldwide to its customers.
Today Helsinn is committed to advancing quality patient care through the development and commercialization of cancer supportive care treatments to benefit both patients and caregivers. Helsinn focuses R&D investments and resources on enhancing cancer supportive care, a still undeserved yet important therapeutic area.
A modern Group focused on growth and development but also tied to tradition and on the values of a family business: in Helsinn more than 500 employees work not only for the health of the patient, but overall for the quality of life of the person.